### **ORGENTEC Diagnostika GmbH**

Carl-Zeiss-Straße 49-51 55129 Mainz - Germany

Phone: +49 (0) 61 31 / 92 58-0 Fax: +49 (0) 61 31 / 92 58-58 Internet: www.orgentec.com





520 3

# ORG 520 Anti-Insulin

#### INTENDED PURPOSE

Anti-Insulin is an ELISA test system for the quantitative measurement of IgG class autoantibodies against insulin in human serum or plasma. This product is intended for professional in vitro diagnostic use only.

Anti-Insulin antibodies are found in a large part of patients with autoimmune diabetes (type 1). These antibodies may be directed against endogenous insulin or against therapeutic insulin preparations of human or animal origin.

#### SYMBOLS USED ON LABELS

| IVD         | In vitro diagnostic medical device      | MICROPLATE   | Microplate       |  |
|-------------|---|--------------|------------------|--|
|             | M                                       | CALIBRATOR A | Calibrator       |  |
|             | Manufacturer                            | CALIBRATOR B | Calibrator       |  |
| REF         | Catalogue number                        | CALIBRATOR C | Calibrator       |  |
| ∑ 96        | Sufficient for 96 determinations        | CALIBRATOR D | Calibrator       |  |
| LOT         | Batch code                              | CALIBRATOR E | Calibrator       |  |
|             | Datch code                              | CALIBRATOR F | Calibrator       |  |
| $\square$   | Use by                                  | CONTROL +    | Control positive |  |
| 2°C - 18°C  | Temperature limitation                  | CONTROL -    | Control negative |  |
| 类           | Keep away from sunlight                 |              |                  |  |
| <u>-</u>    | Do not reuse                            | DILUENT      | Sample Buffer P  |  |
| (2)         | Do not reuse                            | CONJUGATE    | Enzyme Conjugate |  |
| μŊ          | Date of manufacture                     |              |                  |  |
| Ċ€          | CE marked according to 98/79/EC         | ТМВ          | TMB Substrate    |  |
| 6           | 3                                       | STOP         | Stop solution    |  |
| $\square i$ | Consult instructions for use            | WASH         | Wash Buffer      |  |
| 520_3       | Electronic Instruction For Use: version | RTU          | Ready to use     |  |

#### PRINCIPLE OF THE TEST

A mixture of highly purified preparations of bovine, porcine and recombinant human insulin is bound to microwells.

The determination is based on an indirect enzyme linked immune reaction with the following steps:

Specific antibodies in the patient sample bind to the antigen coated on the surface of the reaction wells. After incubation, a washing step removes unbound and unspecifically bound serum or plasma components. Subesquently added enzyme conjugate binds to the immobilized antibody-antigen-complexes. After incubation, a second washing step removes unbound enzyme conjugate. After addition of substrate solution the bound enzyme conjugate hydrolyses the substrate forming a blue coloured product. Addition of an acid stopps the reaction generating a yellow end-product. The intensity of the yellow color correlates with the concentration of the antibody-antigen-complex and can be measured photometrically at 450 nm.

#### WARNINGS AND PRECAUTIONS

- · All reagents of this kit are intended for professional in vitro diagnostic use only.
- Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
- · Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
- Avoid contact with the substrate TMB (3.3'.5.5'-Tetramethyl-benzidine).
- Stop solution contains acid, classifiaction is non-hazardous. Avoid contact with skin.
- Control, sample buffer and wash buffer contain sodium azide 0.09% as preservative. This concentration
  is classified as non-hazardous.
- Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.

During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:

- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove
  contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin,
  wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running
  water for at least 10 minutes. Get medical attention if necessary.
- Personal precautions, protective equipment and emergency procedures:

Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.

- Exposure controls / personal protection: Wear protective gloves of nitril rubber or natural latex. Wear protective glasses. Used according to intended use no dangerous reactions known.
- Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
- · For disposal of laboratory waste the national or regional legislation has to be observed.

Observe the guidelines for performing quality control in medical laboratories by assaying control sera.

#### CONTENTS OF THE KIT

| CONTENTO OF THE RIT |           |  |  |  |  |  |  |
|---------------------|-----------|--|--|--|--|--|--|
| ORG 520             | Σ 96      | Sufficient for 96 determinations   |  |  |  |  |  |
| MICROPLATE          | 1         | One divisible microplate consisting of 12 modules of 8 wells each. Ready to use.                             |  |  |  |  |  |
|                     |           | Product code on module: INS  |  |  |  |  |  |
| CALIBRATOR A        | 1x 1.5 ml | Calibrator A 0 U/ml, containing serum/buffer matrix (PBS, BSA, detergent, NaN3                               |  |  |  |  |  |
|                     |           | 0.09%), yellow. Ready to use.  |  |  |  |  |  |
| CALIBRATOR B        | 1x 1.5 ml | Calibrator B 6.3 U/ml, containing insulin antibodies in a serum/buffer matrix (PBS, BSA,                     |  |  |  |  |  |
|                     |           | detergent, NaN3 0.09%), yellow. Ready to use.  |  |  |  |  |  |
| CALIBRATOR C        | 1x 1.5 ml | Calibrator C 12.5 U/ml, containing insulin antibodies in a serum/buffer matrix (PBS,                         |  |  |  |  |  |
|                     |           | BSA, detergent, NaN3 0.09%), yellow. Ready to use.   |  |  |  |  |  |
| CALIBRATOR D        | 1x 1.5 ml | Calibrator D 25 U/ml, containing insulin antibodies in a serum/buffer matrix (PBS, BSA,                      |  |  |  |  |  |
|                     |           | detergent, NaN3 0.09%), yellow. Ready to use.  |  |  |  |  |  |
| CALIBRATOR E        | 1x 1.5 ml | Calibrator E 50 U/ml, containing insulin antibodies in a serum/buffer matrix (PBS, BSA,                      |  |  |  |  |  |
| [                   |           | NaN3 0.09%), yellow. Ready to use.   |  |  |  |  |  |
| CALIBRATOR F        | 1x 1.5 ml | Calibrator F 100 U/ml, containing insulin antibodies in a serum/buffer matrix (PBS, BSA,                     |  |  |  |  |  |
| [                   |           | detergent, NaN3 0.09%), yellow. Ready to use.  |  |  |  |  |  |
| CONTROL +           | 1x 1.5 ml | Control positive, containing insulin antibodies in a serum/buffer matrix (PBS, BSA,                          |  |  |  |  |  |
|                     |           | detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis. |  |  |  |  |  |
| CONTROL -           | 1v 1 5 ml | Control negative, containing insulin antibodies in a serum/buffer matrix (PBS, BSA,                          |  |  |  |  |  |
| CONTROL             | 11.51111  | detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the                          |  |  |  |  |  |
|                     |           | certificate of analysis.   |  |  |  |  |  |
| DILUENT             | 20 ml     | Sample Buffer P, containing PBS, BSA, detergent, preservative sodium azide 0.09%,                            |  |  |  |  |  |
|                     | 201111    | yellow, concentrate (5 x).   |  |  |  |  |  |
| CONJUGATE           | 15 ml     | Enzyme Conjugate containing anti-human IgG antibodies, HRP labelled; PBS, BSA,                               |  |  |  |  |  |
|                     |           | detergent, preservative PROCLIN 0.05%, light red. Ready to use.  |  |  |  |  |  |
| ТМВ                 | 15 ml     | TMB Substrate; containing 3,3', 5,5'- Tetramethylbenzidin, colorless. Ready to use.                          |  |  |  |  |  |
| STOP                | 15 ml     | Stop solution; contains acid. Ready to use.  |  |  |  |  |  |
| WASH                | 20 ml     | Wash Buffer, containing Tris, detergent, preservative sodium azide 0.09%; 50 x conc.                         |  |  |  |  |  |
| (li)                | 1         | Certificate of Analysis  |  |  |  |  |  |

#### **MATERIALS REQUIRED**

- · Microplate reader capable of endpoint measurements at 450 nm; optional: reference filter at 620 nm
- · Data reduction software
- Multi-channel dispenser or repeatable pipette for 100 μl
- Vortex mixer
- Pipettes for 10 μl, 100 μl and 1000 μl
- · Laboratory timing device
- · Distilled or deionised water
- · Measuring cylinder for 1000 ml and 100 ml
- Plastic container for storage of the wash solution

This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be validated on the respective automated system. Detailed information is provided upon request.

#### SPECIMEN COLLECTION, STORAGE AND HANDLING

- · Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- · Testing of heat-inactivated sera is not recommended.

#### STORAGE AND STABILITY

- . Store test kit at 2-8°C in the dark.
- Do not expose reagents to heat, sun, or strong light during storage and usage.
- Store microplate sealed and dessicated in the clip bag provided.
- Shelf life of the unopended test kit is 18 months from day of production.
   Unopened reagents are stable until expiration of the kit. See labels for individual batch.
- Diluted Wash Buffer and Sample Buffer are stable for at least 30 days when stored at 2-8°C.
   We recommend consumption on the same day.

#### PROCEDURAL NOTES

- Do not use kit components beyond their expiration dates.
- Do not interchange kit components from different lots and products.
- All materials must be at room temperature (20-28°C) prior to use.
- · Prepare all reagents and samples. Once started, performe the test without interruption.
- Double determinations may be done. By this means pipetting errors may become obvious.
- · Perform the assay steps only in the order indicated.
- · Always use fresh sample dilutions.
- · Pipette all reagents and samples into the bottom of the wells.
- To avoid carryover or contamination, change the pipette tip between samples and different kit controls.
- · Wash microwells thoroughly and remove the last droplets of wash buffer.
- · All incubation steps must be accurately timed.
- Do not re-use microplate wells.

#### PREPARATION OF REAGENTS

WASH

Dilute the contents of one vial of the buffered wash solution concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use.

DILUENT

Sample Buffer P: Prior to use dilute the contents (20 ml) of one vial of sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 ml.

#### Preparation of samples

Dilute patient samples 1:100 before the assay: Put 990 µl of prediluted sample buffer in a polystyrene tube and add 10 µl of sample. Mix well. Note: Calibrators / Controls are ready to use and need not be diluted.

#### TEST PROCEDURE

Prepare enough microplate modules for all calibrators / controls and patient samples.

1. Pipette 100 ul of calibrators, controls and prediluted patient samples into the wells.

Incubate for 30 minutes at room temperature (20-28 °C).

Discard the contents of the microwells and wash 3 times with 300 µl of wash solution.

2. Dispense 100 µl of enzyme conjugate into each well.

Incubate for 15 minutes at room temperature.

Discard the contents of the microwells and wash 3 times with 300 µl of wash solution.

3. Dispense 100 µl of TMB substrate solution into each well

Incubate for 15 minutes at room temperature

4. Add 100 µl of stop solution to each well of the modules

Incubate for 5 minutes at room temperature.

Read the optical density at 450 nm (reference 600-690nm) and calculate the results.

The developed colour is stable for at least 30 minutes. Read during this time.

Example for a pipetting scheme:

|   | 1  | 2  | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|----|----|---|---|---|---|---|---|---|----|----|----|
| Α | Α  | P1 |   |   |   |   |   |   |   |    |    |    |
| В | В  | P2 |   |   |   |   |   |   |   |    |    |    |
| С | С  | P3 |   |   |   |   |   |   |   |    |    |    |
| D | D  |    |   |   |   |   |   |   |   |    |    |    |
| Е | Е  |    |   |   |   |   |   |   |   |    |    |    |
| F | F  |    |   |   |   |   |   |   |   |    |    |    |
| G | C+ |    |   |   |   |   |   |   |   |    |    |    |
| Н | C- |    |   |   |   |   |   |   |   |    |    |    |

P1, ... patient sample A-F calibrators C+, C- controls

#### VALIDATION

Test results are valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of Analysis enclosed in each test kit.

If these quality control criteria are not met the assay run is invalid and should be repeated.

#### **CALCULATION OF RESULTS**

For quantitative results plot the optical density of each calibrator versus the calibrator concentration to create a calibration curve. The concentration of patient samples may then be estimated from the calibration curve by interpolation.

Using data reduction software a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice.

#### PERFORMANCE CHARACTERISTICS

# Calibration

This assay system is calibrated in relative arbitrary units, since no international reference preparation is available for this assay.

#### Measuring range

The calculation range of this ELISA assay is 0 - 100 U/ml

#### **Expected values**

In a normal range study with samples from healthy blood donors the following ranges have been established with this ELISA assay: Cut-off 10 U/ml

#### Interpretation of results

Negative: < 10 U/mlPositive:  $\ge 10 \text{ U/ml}$ 

#### Linearity

Patient samples containing high levels of specific antibody were serially diluted in sample buffer to demonstrate the dynamic range of the assay and the upper / lower end of linearity. Activity for each dilution was calculated from the calibration curve using a 4-Parameter-Fit with lin-log coordinates.

| Sample | Dilution | Observed           | Expected | O/E |
|--------|----------|--------------------|----------|-----|
|        |          | U/ml               | U/ml     | [%] |
| 1      | 1:100    | 77.6               | 77.6     | 100 |
|        | 1:200    | 41.7               | 38.8     | 107 |
|        | 1:400    | 21.1               | 19.4     | 109 |
|        | 1:800    | 10.3               | 9.7      | 106 |
|        | 1:1600   | <mark>4.7</mark>   | 4.9      | 96  |
| 2      | 1:100    | <mark>100.7</mark> | 100.7    | 100 |
|        | 1:200    | 50.7               | 50.4     | 101 |
|        | 1:400    | 23.7               | 25.2     | 94  |
|        | 1:800    | 11.1               | 12.6     | 88  |
|        | 1:1600   | 5.3                | 6.3      | 84  |

#### Limit of detection

Functional sensitivity was determined to be: 0.5 U/ml

#### Reproducibility

Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.

Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 6 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.

| Intra-Assay |      |      |  |  |  |
|-------------|------|------|--|--|--|
| Sample      | Mean |      |  |  |  |
|             | U/ml | CV % |  |  |  |
| 1           | 11.2 | 2.5  |  |  |  |
| 2           | 27.6 | 2.9  |  |  |  |
| 3           | 59.7 | 4.0  |  |  |  |

| Inter-Assay |      |      |  |  |  |
|-------------|------|------|--|--|--|
| Sample      | Mean |      |  |  |  |
|             | U/ml | CV % |  |  |  |
| 1           | 11.6 | 6.0  |  |  |  |
| 2           | 31.2 | 5.2  |  |  |  |
| 3           | 69.5 | 4.3  |  |  |  |

#### Interfering substances

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparine). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

#### Study results

| Study population         | <u>n</u> | n Pos | <u>%</u> |
|--------------------------|----------|-------|----------|
| Diabetes mellitus Type I | 100      | 72    | 72.0     |
| Normal human sera        | 160      | 2     | 1.3      |

Clinical Diagnosis
POS NEG
ORG 520 POS 72 2
NEG 28 158
100 160 260
Sensitivity: 72.0 %

Specificity: 98.8 % Overall agreement: 88.5 %

#### LIMITATIONS OF THE PROCEDURE

This assay is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but

should be made by the physician after all clinical and laboratory findings have been evaluated concerning the entire clinical picture of the patient. Also every decision for therapy should be taken individually.

The above pathological and normal reference ranges for antibodies in patient samples should be regarded as recommendations only. Each laboratory should establishe its own ranges according to ISO 15189 or other applicable laboratory guidelines.

#### REFERENCES

- Reeves, W. G. Insulin Antibody Determination: Theoretical and Practical Considerations. Diabetologia 24, 399 (1983).
- 2. Atkinson, M. A., Fisk, D. D., Spillar, R. P. and MacLaren, N. K. Insulin antibodies as markers for Insulin dependent diabetes mellitus (IDD).Diabetes 34, 926 930 (1985).
- 3. Willein, T., Nicholson, S. and Casey, C. A Micro Enzyme-Linked Immunosorbent Assay for Insulin Antibodies in Serum. J. Imm. Methods 76, 185 (1985).
- 4. Kobayashi, N. et al. A Solid-Phase Enzyme Immunoassay for Anti-Insulin Antibody in Diabetes Mellitus Patients. J. Imm. Methods 84, 245 (1985).
- 5. Wissllein, T. et al. Value of Insulin Antibodies as Serum marker for Insulin-Dependent Diabetes Mellitus. Lancet 1, 480 (1985).
- Soeldner, J. S. et al. Insulin-Dependent Diabetes Mellitus and Autoimmunity: Islet-Cell Autoantibodies and beta-Cell Failure. New Engl. J. Med. 313, 893 (1985).
- 7. Torfs, C. P. et al. Long Term Frozen Sera for Epidemiological Studies of Antibodies. Lancet 1, 503 (1986).
- 8. Seino, S. et al. Characterisation of Circulating Insulin in Insulin Autoimmune Syndrome. Clin. Endo. & Metab. 62, 64 (1986).
- Boitard, C. H. and McDewitt, H. O. Immunology of insulin-dependent diabetes mellitus. In. Cohen, J. R., (ed.)
  Perspectives on autoimmunity, 39-58 (1987). CRC Press, Boca Raton, FL Nouvo, J. A., Baker, Jr., J. R.,
  Wartowsky, I. et al. Autoantibodies to insulin are present in sera of patients with autoimmune thyroid diseases.
  Diabetes, 37, 317-320 (1988).
- 10. Witkin, T. J. Insulin Autoantibodies as markers for type I diabetes. Endocrine Reviews, 11, 92-104 (1990).

#### Notice to the user (European Union):

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the EU Member State in which the user and/or the patient is established.

#### Change Control

Former version: ORG 520\_IFU\_EN\_QM113149\_2013-12-16\_1.2 Reason for revision: Introduction electronic IFU on homepage

Pipet 100 μl calibrator, control or patient sample

Incubate for 30 minutes at room temperature

Discard the contents of the wells and wash 3 times with 300 μl wash solution

Pipet 100 μl enzyme conjugate

Incubate for 15 minutes at room temperature

Discard the contents of the wells and wash 3 times with 300 μl wash solution

Pipet 100 μl substrate solution

Incubate for 15 minutes at room temperature

Add 100 μl stop solution

Leave untouched for 5 minutes

Read at 450 nm

According to 1907/2006/EC + amendment 453/2010/EC Document No QM110189 version 3, dated 2018-01-23 valid until 2021-01-23 replaces vers. 2 dated 2015-01-22

# **Safety Data Sheet ORG 520**



# 1. Product identifier

**ORG 520** Code **Anti-Insulin** Name

Anti-Insulin is a medical device for the quantitative detection of IgG class autoantibodies against Insulin in human serum or plasma. Intended for professional in vitro diagnostic use only.

# Manufacturer / Supplier

ORGENTEC Diagnostika GmbH

Carl-Zeiss-Straße 49-51 55129 Mainz - Germany Phone: +49 6131 / 92580 Fax: +49 6131 / 925858 orgentec@orgentec.com www.orgentec.com

# 2. Hazards identification

Product is not classified as hazardous according to the European Regulation 1999/45/EC or 1272/2008/EC. Human health hazards: No specific hazard.

# 3. Composition / Information on ingredients

Coated microplate: Purified antigen coated onto polystyrene microwells.

Calibrators/controls: Human antibodies < 1% in phosphate buffered saline with Tween 20 as detergent,

sodium azide 0.09% as preservative and BSA for stabilization.

Enzyme conjugate: Peroxidase conjugated anti-human antibody < 0.0001% in phosphate buffered saline

with ProClin 300 as preservative and bovine serum albumin (BSA) for stabilization.

Sample buffer: Phosphate buffered saline with sodium azide 0.09% as preservative and BSA for

stabilization.

Wash buffer: Tris buffered saline with Tween 20 as detergent and sodium azide 0.09% as preservative. Substrate solution: Aqueous solution of TMB (3,3',5,5'-Tetramethylbenzidin) 0.032% with organic solvent

2-pyrrolidone < 10%, sodium perborate, citrate, EDTA, and Kathon CG as preservative.

Aqueous solution of phosphoric acid 4.5%. Stop solution:

Active substances in all mixtures do not meet the criteria for classification according to 1272/2008/EC.

# 4. First aid measures

Skin Contact: In case of skin contact, immediately wash thoroughly with water and soap.

Remove contaminated clothing and shoes and wash before reuse.

If stop solution comes into contact with skin, wash thoroughly with water.

Eye Contact: After contact with the eyes carefully rinse the opened eye with running water for at

least 10 minutes. Get medical attention if necessary. Remove contact lenses if this

can be done easily.

Respiratory tract: Take person to the fresh air.

Swallowing: Rinse the mouth and spit the fluids out. Drink 1 - 2 glasses of water immediately. During

spontaneous vomiting hold the head of the casualty low with the body in a prone position in

order to avoid the penetration of vomit into the air tube.

# 5. Firefighting measures

Extinguishing Media: Use dry chemical powder, water spray, foam or carbon dioxide.

# 6. Personal precautions, protective equipment and emergency procedures

Observe laboratory safety regulations.

Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth.

Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled.

When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.

# 7. Handling and storage

Handling: Special measures are not required. Storage: Store at 2 to 8 °C. Protect from light.

# 8. Exposure controls / personal protection

According to 1907/2006/EC + amendment 453/2010/EC Document No QM110189 version 3, dated 2018-01-23 valid until 2021-01-23 replaces vers. 2 dated 2015-01-22

# Safety Data Sheet ORG 520



Respiratory protection: Not required

Hand protection: Wear protective gloves of nitril rubber or natural latex.

Eye protection: Wear protective glasses.

# 9. Physical and chemical properties

Coated microplate:
Calibrators:
Polystyrol microwells in foil pouch.
Yellow fluid in glass bottle.
Red fluid in polyethylene bottle.
Yellow fluid in polyethylene bottle.
Yellow fluid in polyethylene bottle.
Colorless fluid in polyethylene bottle.
Stop solution:
Colorless fluid in polyethylene bottle.
Colorless fluid in polyethylene bottle.

# 10. Stability and reactivity

Stability of components is given on the labels. Used according to intended use no dangerous reactions known.

Conditions to avoid: Substrate solution is light-sensitive. Store substrate solution in the dark.

# 11. Toxicological information

Used according to intended use no toxicological reactions known.

# 12. Ecological information

Used according to intended use no ecological reactions known.

# 13. Disposal considerations

Waste should be disposed of in accordance with federal, state and local environmental control regulations. When disposing of conjugate solution, sample buffer or wash buffer flush drains with copious amounts of water. Disposal of packaging according to the instructions of the public authorities.

# 14. Transport information

This product is not subject to official transport regulations.

## 15. Regulatory information

1907/2006/EC Registration, evaluation and authorization of chemicals regulation (REACH)

1272/2008/EC Classification, labelling and packaging regulation (CLP, globally harmonized system GHS) replaces 67/548/EWG and 1999/45/EG, amending 1907/2006/EG

453/2010/EC Compilation of safety data sheets regulation (SDS), amending 1907/2006/EC

This product is not classified according to the EU regulations 1272/2008. No labeling requirement.

# 16. Other information

Revision: prolonging validity for 3 years; editorial corrections.

Safety data for product including all components. This product is intended for professional laboratory use only.

# Notice to Reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier assumes any liability whatsoever for the accuracy or completeness of the information contained herein. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.